

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M.10246 • HELLMAN & FRIEDMAN / CORDIS**

## **SECTION 1.2**

### **Description of the concentration**

The notified concentration involves the proposed acquisition of sole control by funds advised by Hellman & Friedman LLC (“**Hellman & Friedman**”) of the Cordis business of Cardinal Health, Inc. (respectively “**Cordis**” and “**Cardinal Health**”) (the “**Proposed Transaction**”).

Hellman & Friedman is a private equity firm focused on market-leading firms with growth potential, and has investments in a variety of sectors worldwide. It has offices in San Francisco, New York and London. More information about Hellman & Friedman can be found at [www.hf.com](http://www.hf.com).

Cordis is a developer and manufacturer of interventional vascular technology, with operations in countries around the world. Cordis is currently part of the Cardinal Health group. Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. It has operations in more than 40 countries and approximately 48,000 employees globally. More information about Cordis and Cardinal Health can be found, respectively, at [https://www.cardinalhealth.co.uk/en\\_gb/medical-products/cordis-products.html](https://www.cardinalhealth.co.uk/en_gb/medical-products/cordis-products.html) and <https://www.cardinalhealth.com>.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE  
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: [COMP-MERGER-REGISTRY@ec.europa.eu](mailto:COMP-MERGER-REGISTRY@ec.europa.eu).